Editas Medicine (EDIT) Leases (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Leases data on file, last reported at $16.1 million in Q4 2025.

• Quarterly Leases fell 50.48% year-over-year to $16.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.1 million (down 50.48% YoY) and the FY2025 annual result came in at $16.1 million, down 50.48% from the prior year.
• Leases retreated to $16.1 million in Q4 2025 per EDIT's latest filing, from $17.6 million in the prior quarter.
• Across five years, Leases topped out at $43.6 million in Q4 2022 and bottomed at $16.1 million in Q4 2025.
• The 5-year median for Leases is $29.8 million (2021), against an average of $28.8 million.
• The widest annual swing landed in 2023, when Leases soared 68.45%; it then sank 50.79% in 2025.
• Tracing EDIT's Leases over 5 years: stood at $26.2 million in 2021, then jumped by 66.77% to $43.6 million in 2022, then decreased by 22.84% to $33.7 million in 2023, then retreated by 3.34% to $32.6 million in 2024, then sank by 50.48% to $16.1 million in 2025.
• Per Business Quant, the three latest EDIT Leases figures stand at $16.1 million (Q4 2025), $17.6 million (Q3 2025), and $19.0 million (Q2 2025).

Peer Comparison